| Subsidiaries and Associates The number of consolidated subsidiaries decreased by 11 in the year ended March 31, 2025, primarily due to liquidations and mergers to reorganize capital in subsidiaries. The number of associates accounted for using the equity method decreased by 1 primarily due to a divestiture and change of ownership ratio. The following is a listing of the Company’s consolidated subsidiaries (including partnerships): 158 subsidiaries as of March 31, 2025 | | | | | | | | | | | | | | | | | | | Company name | | Country | | Ownership of Voting Rights (%) | | | Takeda Argentina S.A. | | Argentina | | 100.0% | | | Takeda Austria GmbH | | Austria | | 100.0% | | | Takeda Manufacturing Austria AG | | Austria | | 100.0% | | | Baxalta Innovations GmbH | | Austria | | 100.0% | | | Baxalta Belgium Manufacturing S.A. | | Belgium | | 100.0% | | | Takeda Distribuidora Ltda. | | Brazil | | 100.0% | | | Takeda Pharma Ltda. | | Brazil | | 100.0% | | | Takeda Canada Inc. | | Canada | | 100.0% | | | Takeda APAC Biopharmaceutical Research and Development Co., Ltd. | | China | | 100.0% | | | Takeda (China) Holdings Co., Ltd. | | China | | 100.0% | | | Takeda (China) International Trading Co., Ltd. | | China | | 100.0% | | | Tianjin Takeda Pharmaceuticals Co., Ltd. | | China | | 100.0% | | | Takeda France S.A.S. | | France | | 100.0% | | | Takeda GmbH | | Germany | | 100.0% | | | Takeda Ireland Limited | | Ireland | | 100.0% | | | Shire Acquisitions Investments Ireland Designated Activity Company | | Ireland | | 100.0% | | | Shire Ireland Finance Trading Limited | | Ireland | | 100.0% | | | Takeda Italia S.p.A. | | Italy | | 100.0% | | | Takeda Pharmaceuticals Korea Co., Ltd. | | Korea | | 100.0% | | | Takeda Mexico S.A.de C.V. | | Mexico | | 100.0% | | | Takeda Nederland B.V. | | Netherlands | | 100.0% | | | Takeda Pharmaceuticals Limited Liability Company | | Russia | | 100.0% | | | Takeda Development Center Asia, Pte. Ltd. | | Singapore | | 100.0% | | | Takeda Manufacturing Singapore Pte. Ltd. | | Singapore | | 100.0% | | | Takeda Farmaceutica Espana S.A. | | Spain | | 100.0% | | | Takeda Pharma AB | | Sweden | | 100.0% | | | Takeda Pharmaceuticals International AG | | Switzerland | | 100.0% | | | Baxalta Manufacturing S.à r.l. | | Switzerland | | 100.0% | | | Takeda Pharma AG | | Switzerland | | 100.0% | | | Takeda İlaç Sağlık Sanayi Ticaret Limited Şirketi | | Turkey | | 100.0% | | | Takeda UK Limited | | United Kingdom | | 100.0% | | | Takeda Pharmaceuticals U.S.A., Inc. | | U.S. | | 100.0% | | | Takeda Vaccines, Inc. | | U.S. | | 100.0% | | | Takeda Development Center Americas, Inc. | | U.S. | | 100.0% | | | Baxalta Incorporated | | U.S. | | 100.0% | | | Dyax Corp. | | U.S. | | 100.0% | | | Takeda Ventures, Inc. | | U.S. | | 100.0% | | | Baxalta US Inc. | | U.S. | | 100.0% | |
| | | | | | | | | | | | | | | | | | | Company name | | Country | | Ownership of Voting Rights (%) | | | Shire Human Genetic Therapies, Inc. | | U.S. | | 100.0% | | | BioLife Plasma Services LP | | U.S. | | 100.0% | | | Takeda Manufacturing U.S.A., Inc. | | U.S. | | 100.0% | | | Takeda Pharmaceuticals America, Inc. | | U.S. | | 100.0% | | Other 116 subsidiaries | | | | | | | | | | | |
|